Axsome Therapeutics (AXSM) Operating Leases (2023 - 2025)
Historic Operating Leases for Axsome Therapeutics (AXSM) over the last 3 years, with Q3 2025 value amounting to $23.0 million.
- Axsome Therapeutics' Operating Leases rose 25777.95% to $23.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.0 million, marking a year-over-year increase of 25777.95%. This contributed to the annual value of $6.0 million for FY2024, which is 1405.83% down from last year.
- Latest data reveals that Axsome Therapeutics reported Operating Leases of $23.0 million as of Q3 2025, which was up 25777.95% from $23.6 million recorded in Q2 2025.
- Over the past 5 years, Axsome Therapeutics' Operating Leases peaked at $23.9 million during Q1 2025, and registered a low of $6.0 million during Q4 2024.
- Its 3-year average for Operating Leases is $11.9 million, with a median of $7.4 million in 2023.
- As far as peak fluctuations go, Axsome Therapeutics' Operating Leases plummeted by 1626.58% in 2024, and later soared by 25777.95% in 2025.
- Axsome Therapeutics' Operating Leases (Quarter) stood at $7.0 million in 2023, then decreased by 14.06% to $6.0 million in 2024, then surged by 281.09% to $23.0 million in 2025.
- Its Operating Leases stands at $23.0 million for Q3 2025, versus $23.6 million for Q2 2025 and $23.9 million for Q1 2025.